Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Day, NC; Kumar, S; Criner, G; Dransfield, M; Halpin, DMG; Han, MK; Jones, CE; Kaisermann, MC; Kilbride, S; Lange, P; Lomas, DA; Martin, N; Martinez, FJ; Singh, D; Wise, R; Lipson, DA

Day, NC (corresponding author), GlaxoSmithKline, Stockley Pk West,1-3 Ironbridge Rd, Uxbridge UB11 1BT, Middx, England.

RESPIRATORY RESEARCH, 2020; 21 (1):

Abstract

Background: This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-inhaler triple therapy with fluticasone furoate/umecli......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索